Cipla Gulf expands partnership with Alvotech

Cipla’s Gulf subsidiary expands partnership with Alvotech to market four drugs in Australia and New Zealand: 

Cipla’s Gulf subsidiary has decided to expand its partnership with Alvotech [1] . The partnership is to commercialize four drugs in Australia and New Zealand, as announced on 2 March 2021. This move aims to facilitate the marketing and distribution of these four biosimilar drugs in the two countries.

Per this alliance, Cipla Gulf will be responsible for commercializing the patented biosimilars, including Aflibercept, Ustekimumab, Denosumab, and Golimumab. Biosimilars are leading products of the drug major and cover different therapeutic categories. Such drugs belong to the following categories – immunology, osteoporosis, oncology, and ophthalmology.

These products will be manufactured by Alvotech and distributed by Cipla Gulf. The subsidiary will use its distribution networks in Australia and New Zealand.

In July 2019, Cipla Gulf had collaborated with Alvotech for a similar agreement. The purpose of the agreement was to commercialize AVT02, an adalimumab biosimilar in select emerging markets.

Cipla hopes to establish a pan therapy presence in the specialties segment. It also expects this move to improve its footprint in the Australian market.

Read more